Michael Berman is a medical device entrepreneur who works with a select group of high-potential development and early-stage commercial companies. In 2000, he co-founded Velocimed, LLC, an endovascular and cardiology incubator, which is a RiverVest Fund I portfolio company.
As former president of Boston Scientific, Mr. Berman expanded the company’s presence in the interventional cardiology market. Under his leadership, the company increased worldwide sales from $300 million to $1.5 billion; fully integrated four acquired interventional cardiology businesses; invested more than $250 million in research and technology; and introduced more than 40 new products.
Mr. Berman is a co-founder and board member of etherworks, Inc.; Apnex, Inc.; Benechill, Inc; BridgePoint, Inc.; Conceptx, Inc.; and Sage Medical, Inc. He also serves on the boards of CoAxia, Inc.; Lutonix, Inc.; PharmaCentra, Inc.; Transoma Medical, Inc.; and UltraShape, Ltd. These companies have raised a cumulative $180 million during his tenure.
Mr. Berman earned his M.B.A. and B.S. from Cornell University.